News
Latest news and updates on the project.
June 2018
Amendment EU, Periodic report, (Ready for) Submission
Protocol final, ICF and patient info final, Other documents for submission final, EU amendment Part A and B final, EU Technical Report part B final, CTA final and signed, Finalizing deliverables
New Data
New data with three tumour models form the M-lab of precision medicine showing that immunocytokines, used in ImmunoSABR, worked better than checkpoint inhibitors with radiation.
May 2018
New Participant
Presentation by Professor Philippe Lambin in Antwerpen on ImmunoSABR led to them becoming a participant
April 2018
Presentation – Barcelona
Presentation by Professor Philippe Lambin (The M-Lab of Precision medicine) given at the ESTRO meeting in Barcelona on novel immunotherapy radiotherapy strategies Presentation by Damienne Marcus (The M-Lab of Precision medicine) given at the ESTRO meeting in Barcelona in on immunocytokines and radiation
March 2018
Presentation – Utrecht
Presentation by Professor Philippe Lambin given at the NVRO-NVRB meeting in Utrecht in on immunocytokines and radiation
January 2018
CRO
Tender (Negometrix), Submissions, Safety reporting, Risk analysis, Local monitors (visits), Training partners, Trial master file
March 2017
Kick Off Meeting – Presentation
First presentation was given by Professor Philippe Lambin , Brussels Kick off meeting introducing ImmunoSABR for a broad audience.
January 2017
H2020 Grant
H2020 grant – We received an H2020 grant from the European Union that helps us to cover the financial part for this study. We are working with a number of hospitals and centres throughout the European Union and aim to encompass patients within the whole of the EU
STAY INFORMED ?
If you want to stay informed about ImmunoSABR project, please subscribe to our newsletter.
CONTACT
The D-Lab / Precision Medicine
P.O. Box 616,
6200 MD Maastricht, The Netherlands
FUNDING
This project has received funding from the European Union’s. Horizon 2020 research and innovation programme under grant agreement No 733008
